Recently added

Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies

Bröckelmann, Paul J; Cliff, Edward; Simon, Florian; Horowitz, Mary; Keating, Armand; IACOBONI, GLORIA (Elsevier, 2025-06)

Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)

Sierra-Rodero, Belen; Martínez-Toledo, Cristina; Molina-Alejandre, Marta; Gil-González, Ángeles; Nadal, Ernest; Garcia Campelo, Rosario; MARTINEZ-MARTI, ALEX (Taylor & Francis, 2025)

Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination

Martin-Martin, Natalia; Garcia-Longarte, Saioa; Lazcano, Uxue; Astobiza, Ianire; Bozal Basterra, Laura; Herranz Martín, Nicolás; Salca, Andrei; Corres-Mendizabal, Jon; Mateo, Joaquin (BMC, 2025-06-03)

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA

Ciuleanu, Tudor Eliade; Zurawski, B.; Menezes, J.; Carbone, David; cobo, manuel; Schenker, Michael; FELIP, ENRIQUETA (Elsevier, 2025-06)

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial

Vallieres, Eric; Vynnychenko, Ihor O.; altorki, nasser; Zhou, Caicun; Csoszi, Tibor; FELIP, ENRIQUETA; MARTINEZ-MARTI, ALEX (American Society of Clinical Oncology, 2025-07-20)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies

Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)

Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies ﻿

Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) ﻿

Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination ﻿

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA ﻿

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial ﻿

Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies

Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)

Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial